Abstract

Dear Editor, In a recent study by Mahmoodi et al. [1] in which they investigated the association between Human leukocyte antigens (HLA) class II alleles and breast cancer, they found that HLA-DQA1*0301 allele is mainly associated with increased risk of breast cancer including early-onset of the cancer. In addition, they found significant association of HLADRB1*1303 allele with susceptibility and the significant participation of HLA-DQA1*0505, HLA-DQB1*0602, HLA-DQA1*0101, HLA-DRB1*1301 and HLADRB1*0101 alleles in protection in entire patients. The results support the hypothesis of “variation of the inherited HLA alleles play a key role in regulating the cytotoxic T lymphocytes against breast tumor antigens”. In one of our study [2], according to the results of HLA class II allele analyses in 69 breast cancer patients, we proposed that HLA-DRB1*03, HLADQB1*02, HLADRB1*13, and HLA-DQB1*06 alleles might be involved in protection against breast cancer and good prognosis. According to results of both studies, it is thought that those who have HLA-DRB1*13, and HLA-DQB1*06 alleles might be resistant to breast cancer development. Taken together, it is thought that typing these special HLA class II alleles could carry a prognostic importance and consequently these protective alleles could have a potential use in either prophylaxis or treatment. In future by determining allele types a systematical screening and follow-up systems can be developed for patients who are at high risk. Furthermore, this knowledge could be used for the development of individual immunotherapeutic treatment modalities.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call